FDA Accepts Bristol-Myers Squibb’s BLA For Belatacept
For filing and reviewing, the company’s submission of a biologic license application for belatacept
Bristol-Myers Squibb has announced that FDA has accepted its submission of a biologic license application for belatacept, for filing and review. Belatacept is in ongoing phase III development for use in kidney transplantation.
Elliott Sigal, executive vice president, chief scientific officer and president, R&D at Bristol-Myers Squibb, said: “Belatacept has the potential to address significant unmet medical needs of transplant patients. We are pleased the FDA has accepted our submission and we look forward to continuing to work with the agency.”
Belatacept, an investigational agent under development, is intended to help prevent graft rejection and maintain kidney function following renal transplantation. Belatacept is being studied to assess its efficacy and safety as a maintenance immunosuppressant agent, said the company.
Related Insight
Suppliers Directory
SCM Pharma - Sterile Manufacturing and Aseptic Filling of Liquids, Gels and Powders (Including Cytotoxic and C14 Radiolabled Drugs) Into Vials, Ampoules, Syringes and Cartridges
SCM Pharma is UK-based pharmaceutical contract manufacturing organisation (CMO) that works with clients progressing drugs through clinical trials and others that require low volume commercial supply of niche licensed products.
Suppliers
Anton Paar - Measuring and Analytical Pharmaceutical Instruments
Anton Paar GmbH produces and distributes high-quality measuring and analytical instruments for industry and research. In the fields of density and concentration measurement, rheometry and CO2 measurement we are the global market leader. Over 1100 employees worldwide strive to provide our customers with optimal instruments and the best possible support.
Suppliers
ISOCHEM - Fine Chemicals for the Pharmaceutical Industry
ISOCHEM, one of the leading suppliers of fine chemistry, is a 40 years old company with about 500 employees world wide. The Head office is located near Paris, in Vert-Le-Petit, France, on one of its five industrial sites.
Suppliers
DSM - Active Pharmaceutical Ingredients and Registered Intermediates
DSM is fully aligned with the needs of pharma and biotech, offering committed partnerships that apply our broad technologies, exceptional facilities, and regulatory excellence to the manufacture of customers’ products.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Safety First
Published by CoreLab Partners
White Papers
Best Practice Clinical Trial Pricing Using Benchmark Data
Published by Medidata Solutions
White Papers
Contamination Concerns
Published by Phage Consultants
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.